Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.78
DXR's Cash-to-Debt is ranked lower than
56% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. DXR: 0.78 )
Ranked among companies with meaningful Cash-to-Debt only.
DXR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: No Debt Max: No Debt
Current: 0.78
Equity-to-Asset 0.77
DXR's Equity-to-Asset is ranked higher than
78% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. DXR: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
DXR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.69 Max: 0.85
Current: 0.77
0.42
0.85
WACC vs ROIC
3.75%
-51.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % 12.17
DXR's Operating Margin % is ranked higher than
97% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. DXR: 12.17 )
Ranked among companies with meaningful Operating Margin % only.
DXR' s Operating Margin % Range Over the Past 10 Years
Min: -355.05  Med: -254.44 Max: 281.17
Current: 12.17
-355.05
281.17
Net Margin % 6.85
DXR's Net Margin % is ranked lower than
92% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. DXR: 6.85 )
Ranked among companies with meaningful Net Margin % only.
DXR' s Net Margin % Range Over the Past 10 Years
Min: -1031.12  Med: 120.33 Max: 858.77
Current: 6.85
-1031.12
858.77
ROE % -38.06
DXR's ROE % is ranked lower than
70% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. DXR: -38.06 )
Ranked among companies with meaningful ROE % only.
DXR' s ROE % Range Over the Past 10 Years
Min: -46.89  Med: 3.96 Max: 30.74
Current: -38.06
-46.89
30.74
ROA % -24.51
DXR's ROA % is ranked lower than
70% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. DXR: -24.51 )
Ranked among companies with meaningful ROA % only.
DXR' s ROA % Range Over the Past 10 Years
Min: -27.33  Med: 2.42 Max: 16.86
Current: -24.51
-27.33
16.86
3-Year Revenue Growth Rate -33.80
DXR's 3-Year Revenue Growth Rate is ranked lower than
81% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. DXR: -33.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DXR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -60  Med: 5.4 Max: 44.1
Current: -33.8
-60
44.1
3-Year EBITDA Growth Rate -70.10
DXR's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. DXR: -70.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DXR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.1  Med: 1.6 Max: 69.8
Current: -70.1
-70.1
69.8
GuruFocus has detected 6 Warning Signs with Daxor Corp $DXR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DXR's 30-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DXR Guru Trades in Q2 2016

Jim Simons 53,800 sh (+0.94%)
» More
Q3 2016

DXR Guru Trades in Q3 2016

Jim Simons 54,000 sh (+0.37%)
» More
Q4 2016

DXR Guru Trades in Q4 2016

Jim Simons 54,300 sh (+0.56%)
» More
Q1 2017

DXR Guru Trades in Q1 2017

Jim Simons 54,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DXR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:LDSYF, NAS:CASM, NAS:PDEX, NAS:ATEC, NAS:BMRA, NAS:BLFS, AMEX:INFU, AMEX:ISR, NAS:VLRX, AMEX:RVP, OTCPK:REPR, OTCBB:NEPH, OTCPK:STXS, NAS:AKER, OTCPK:IGAP, AMEX:MLSS, NAS:SKLN, OTCPK:UEEC, NAS:EKSO, OTCPK:VPTDF » details
Headquarter Location:USA
Daxor Corp is an investment company with medical instrumentation and biotechnology operations. It provides original medical equipment for medical personnel. It manufactures machine that provides rapid direct measurement of a patient's blood volume.

Daxor Corp was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.

Top Ranked Articles about Daxor Corp

Daxor Corporation Announces Hiring of Chief Financial Officer

NEW YORK, NY--(Marketwired - Jun 17, 2016) - Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the hiring of Eric P. Coleman as its new Chief Financial Officer effective June 6, 2016, reporting directly to Michael Feldschuh, Acting President & CEO of Daxor Corporation. "Mr. Coleman will be responsible for overseeing the financial activities of Daxor and will help lead in the ongoing restructuring of the company as well as negotiating joint ventures and corporate actions to enhance shareholder value in a transformative way," said Mr. Feldschuh. Eric is a licensed CPA and has more than 25 years of finance leadership experience, including tenures with high-profile international public companies. His experience spans financial management and risk management in the technology sectors complemented by several years in the manufacturing and medical device industries. He is passionate about improving processes to increase market value and possesses a deep understanding of accounting, tax, payroll, and finance, in both large and small enterprises. His knowledge of international settings and cultures gives him unique insight in working with diverse groups to create effective, seamless, and high performing teams. He received his Bachelor's Degree in Accounting from Xavier University. Mr. Coleman stated, "I am thrilled to join Daxor. The strategic growth opportunities for the company are compelling, and the mission of saving lives has never been more important. Daxor's BVA-100 Blood Volume Analyzer is a lifesaving diagnostic used at leading hospitals in the country. I look forward to being an integral part of the team at Daxor and helping to drive further success for the company." Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:

Lisa Quartley

Senior Vice President, Marketing and Commercial Development

212-330-8518

[email protected]





Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.29
DXR's PE Ratio is ranked lower than
99.99% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. DXR: 18.29 )
Ranked among companies with meaningful PE Ratio only.
DXR' s PE Ratio Range Over the Past 10 Years
Min: 3.11  Med: 9.05 Max: 64.81
Current: 18.29
3.11
64.81
PE Ratio without NRI 18.29
DXR's PE Ratio without NRI is ranked lower than
99.99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. DXR: 18.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
DXR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.11  Med: 9.05 Max: 64.81
Current: 18.29
3.11
64.81
Price-to-Owner-Earnings 2.30
DXR's Price-to-Owner-Earnings is ranked lower than
99.99% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. DXR: 2.30 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DXR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.47
Current: 2.3
0
2.47
PB Ratio 1.73
DXR's PB Ratio is ranked higher than
74% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. DXR: 1.73 )
Ranked among companies with meaningful PB Ratio only.
DXR' s PB Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.11 Max: 2.12
Current: 1.73
0.73
2.12
EV-to-EBIT 211.08
DXR's EV-to-EBIT is ranked lower than
98% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. DXR: 211.08 )
Ranked among companies with meaningful EV-to-EBIT only.
DXR' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.4  Med: -7.7 Max: 227.4
Current: 211.08
-21.4
227.4
EV-to-EBITDA 211.08
DXR's EV-to-EBITDA is ranked lower than
98% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. DXR: 211.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
DXR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.3  Med: -8.2 Max: 227.4
Current: 211.08
-22.3
227.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.43
DXR's Dividend Yield % is ranked lower than
89% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. DXR: 0.43 )
Ranked among companies with meaningful Dividend Yield % only.
DXR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.4  Med: 3.49 Max: 11.38
Current: 0.43
0.4
11.38
Dividend Payout Ratio 0.08
DXR's Dividend Payout Ratio is ranked lower than
99.99% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. DXR: 0.08 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DXR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.24 Max: 0.86
Current: 0.08
0.08
0.86
3-Year Dividend Growth Rate -15.70
DXR's 3-Year Dividend Growth Rate is ranked lower than
92% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. DXR: -15.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DXR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -15.7
Current: -15.7
Forward Dividend Yield % 0.43
DXR's Forward Dividend Yield % is ranked lower than
92% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. DXR: 0.43 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.01
DXR's 5-Year Yield-on-Cost % is ranked lower than
100% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. DXR: 0.01 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DXR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.01  Med: 0.12 Max: 0.39
Current: 0.01
0.01
0.39
3-Year Average Share Buyback Ratio 2.40
DXR's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. DXR: 2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 1 Max: 3
Current: 2.4
-0.3
3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.72
DXR's Price-to-Tangible-Book is ranked higher than
81% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. DXR: 1.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DXR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63  Med: 1.54 Max: 2.63
Current: 1.72
0.63
2.63
Earnings Yield (Greenblatt) % 0.48
DXR's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. DXR: 0.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DXR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.44  Med: 3.3 Max: 4
Current: 0.48
0.44
4
Forward Rate of Return (Yacktman) % -25.22
DXR's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. DXR: -25.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DXR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -27.8  Med: -13.3 Max: 24.2
Current: -25.22
-27.8
24.2

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ 0.38
Beta0.31
Short Percentage of Float0.14%
52-Week Range $6.55 - 9.80
Shares Outstanding (Mil)3.80
» More Articles for DXR

Headlines

Articles On GuruFocus.com
Daxor Corporation Announces Hiring of Chief Financial Officer Jun 17 2016 
Real-World Impact on Heart Failure Mortality and Readmissions of Individualized Care Guided by Blood Apr 06 2016 
University of Hawaii and The Queen's Medical Center Reports on a Study on Critically Ill Patients Ut Mar 09 2016 
Daxor Corporation Announces Upcoming Filing of Form N-CSR for December 31, 2015 and Recent Developme Feb 29 2016 
Daxor Corporation Announces Return of Dr. Joseph Feldschuh After Pancreatic Cancer Surgery Feb 17 2016 
Daxor Corporation Announces Sale of BVA-100 Blood Volume Analyzer to Nebraska Medicine Feb 08 2016 
Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as Presid Dec 10 2015 
Heart Failure Research From the Mayo Clinic Utilizing the BVA-100 Blood Volume Analyzer Presented at Oct 01 2015 
Taglich Brothers Initiates Coverage of Daxor Corporation Sep 04 2015 
Daxor Announces Hire of Senior Vice President, Marketing and Commercial Development Sep 02 2015 

More From Other Websites
ETFs with exposure to Daxor Corp. : May 23, 2017 May 23 2017
Daxor Corp. :DXR-US: Earnings Analysis: 2016 By the Numbers : May 2, 2017 May 02 2017
Daxor Corporation Announces Delay in Filing of Form N-CSR for December 31, 2016, and the Uniformed... Apr 10 2017
Daxor Corporation Announces Death of Founder, Chief Medical Officer, and Developer of Blood Volume... Feb 01 2017
SCCM17 Randomized Controlled Trial Analysis: Individualized Volume Management Guided by Direct Blood... Jan 30 2017
ETFs with exposure to Daxor Corp. : January 19, 2017 Jan 19 2017
Huge Michael Dell Purchase Highlights Insider Buying: Dell Technologies, Accelerate Diagnostics,... Jan 15 2017
Daxor Corporation Announces Dividend, Patent Approval, Title Change Nov 18 2016
Daxor Corporation Announces Two New Studies From the Mayo Clinic and Lankenau Medical Center... Sep 29 2016
Daxor Corp. :DXR-US: Earnings Analysis: For the six months ended June 30, 2016 : September 27, 2016 Sep 27 2016
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2016 Sep 15 2016
In Heart Failure, One Size Does Not Fit All: New Mayo Clinic BVA Study Published in Journal of the... Jul 27 2016
Daxor Corporation Announces Hiring of Chief Financial Officer Jun 17 2016
Real-World Impact on Heart Failure Mortality and Readmissions of Individualized Care Guided by Blood... Apr 06 2016
University of Hawaii and The Queen's Medical Center Reports on a Study on Critically Ill Patients... Mar 09 2016
Daxor Corporation Announces Upcoming Filing of Form N-CSR for December 31, 2015 and Recent... Feb 29 2016
Daxor Corporation Announces Return of Dr. Joseph Feldschuh After Pancreatic Cancer Surgery Feb 17 2016
Daxor Corporation Announces Sale of BVA-100 Blood Volume Analyzer to Nebraska Medicine Feb 08 2016
Technical Data Drives the Market - Analyst Review of Orkla, Magic Software Enterprises, Iao Kun... Jan 29 2016
Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as... Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat